Your browser doesn't support javascript.
loading
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Chowdhury, Shrabanti; Kennedy, Jacob J; Ivey, Richard G; Murillo, Oscar D; Hosseini, Noshad; Song, Xiaoyu; Petralia, Francesca; Calinawan, Anna; Savage, Sara R; Berry, Anna B; Reva, Boris; Ozbek, Umut; Krek, Azra; Ma, Weiping; da Veiga Leprevost, Felipe; Ji, Jiayi; Yoo, Seungyeul; Lin, Chenwei; Voytovich, Uliana J; Huang, Yajue; Lee, Sun-Hee; Bergan, Lindsay; Lorentzen, Travis D; Mesri, Mehdi; Rodriguez, Henry; Hoofnagle, Andrew N; Herbert, Zachary T; Nesvizhskii, Alexey I; Zhang, Bing; Whiteaker, Jeffrey R; Fenyo, David; McKerrow, Wilson; Wang, Joshua; Schürer, Stephan C; Stathias, Vasileios; Chen, X Steven; Barcellos-Hoff, Mary Helen; Starr, Timothy K; Winterhoff, Boris J; Nelson, Andrew C; Mok, Samuel C; Kaufmann, Scott H; Drescher, Charles; Cieslik, Marcin; Wang, Pei; Birrer, Michael J; Paulovich, Amanda G.
Afiliación
  • Chowdhury S; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Kennedy JJ; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Ivey RG; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Murillo OD; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Hosseini N; Department of Computational Medicine and Bioinformatics, Michigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA.
  • Song X; Tisch Cancer Institute, Department of Population Health Science and Policy, Institute for Health Care Delivery Science, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Petralia F; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Calinawan A; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Savage SR; Lester and Sue Smith Breast Center, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
  • Berry AB; Syapse, Inc., San Francisco, CA 94115, USA.
  • Reva B; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Ozbek U; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Krek A; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Ma W; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • da Veiga Leprevost F; Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA.
  • Ji J; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Yoo S; Sema4, Inc., Stamford, CT 06902, USA.
  • Lin C; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Voytovich UJ; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Huang Y; Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN 55905, USA.
  • Lee SH; Departments of Oncology and Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
  • Bergan L; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Lorentzen TD; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Mesri M; Office of Cancer Clinical Proteomics Research, National Cancer Institute, Rockville, MD 20850, USA.
  • Rodriguez H; Office of Cancer Clinical Proteomics Research, National Cancer Institute, Rockville, MD 20850, USA.
  • Hoofnagle AN; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
  • Herbert ZT; Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Nesvizhskii AI; Department of Pathology, Department of Computational Medicine and Bioinformatics, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA.
  • Zhang B; Lester and Sue Smith Breast Center, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
  • Whiteaker JR; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Fenyo D; Institute for Systems Genetics, NYU School of Medicine, New York, NY 10016, USA.
  • McKerrow W; Institute for Systems Genetics, NYU School of Medicine, New York, NY 10016, USA.
  • Wang J; Institute for Systems Genetics, NYU School of Medicine, New York, NY 10016, USA.
  • Schürer SC; Department of Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, and Institute for Data Science & Computing, University of Miami, Miami, FL 33136, USA.
  • Stathias V; Department of Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, and Institute for Data Science & Computing, University of Miami, Miami, FL 33136, USA.
  • Chen XS; Department of Public Health Sciences, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
  • Barcellos-Hoff MH; Helen Diller Family Comprehensive Cancer Center, Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94115, USA.
  • Starr TK; Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN 55455, USA.
  • Winterhoff BJ; Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN 55455, USA.
  • Nelson AC; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA.
  • Mok SC; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Kaufmann SH; Departments of Oncology and Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
  • Drescher C; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Cieslik M; Department of Pathology, Department of Computational Medicine and Bioinformatics, Michigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA. Electronic address: mcieslik@med.umich.edu.
  • Wang P; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: pei.wang@mssm.edu.
  • Birrer MJ; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. Electronic address: mjbirrer@uams.edu.
  • Paulovich AG; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: apaulovi@fredhutch.org.
Cell ; 186(16): 3476-3498.e35, 2023 08 03.
Article en En | MEDLINE | ID: mdl-37541199
ABSTRACT
To improve the understanding of chemo-refractory high-grade serous ovarian cancers (HGSOCs), we characterized the proteogenomic landscape of 242 (refractory and sensitive) HGSOCs, representing one discovery and two validation cohorts across two biospecimen types (formalin-fixed paraffin-embedded and frozen). We identified a 64-protein signature that predicts with high specificity a subset of HGSOCs refractory to initial platinum-based therapy and is validated in two independent patient cohorts. We detected significant association between lack of Ch17 loss of heterozygosity (LOH) and chemo-refractoriness. Based on pathway protein expression, we identified 5 clusters of HGSOC, which validated across two independent patient cohorts and patient-derived xenograft (PDX) models. These clusters may represent different mechanisms of refractoriness and implicate putative therapeutic vulnerabilities.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso / Proteogenómica Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Cell Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso / Proteogenómica Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Cell Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos